Item 5.02 Departure of Directors or Principal Officers; Election of Directors;
Appointment of Principal Officers.
(b) Effective July 3, 2023, Dr. Rupert Vessey, Executive Vice President,
Research and Early Development, has decided to leave Bristol-Myers Squibb
Company (the "Company").
(e) In connection with his departure, Dr. Vessey will be entitled to (i)
severance benefits in accordance with the Company's Senior Executive Severance
Plan, and (ii) (A) pro-rated vesting of Market Share Units (MSUs) and
Performance Share Units (PSUs) and (B) full vesting of his 2019 Restricted Stock
Units Inducement Award, in each case, in accordance with the Company's equity
award agreements under the Company's 2012 and 2021 Stock Award and Incentive
Plans. In addition, Dr. Vessey will receive a pro-rated annual incentive payout
for 2023 in the amount of $550,855.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
The following exhibit is included as part of this Current Report on Form 8-K:
Exhibit
No. Description
104 The cover page from this Current Report on Form 8-K formatted in Inline
XBRL (included as Exhibit 101).
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses